TY - JOUR
T1 - Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
AU - Reale, Maria Lucia
AU - Chiari, Rita
AU - Tiseo, Marcello
AU - Vitiello, Fabiana
AU - Barbieri, Fausto
AU - Cortinovis, Diego
AU - Ceresoli, Giovanni Luca
AU - Finocchiaro, Giovanna
AU - Romano, Gianpiero Diego
AU - Piovano, Pier Luigi
AU - Del Conte, Alessandro
AU - Borra, Gloria
AU - Verderame, Francesco
AU - Scotti, Vieri
AU - Nonnis, Daniela
AU - Galetta, Domenico
AU - Sergi, Concetta
AU - Migliorino, Maria Rita
AU - Tonini, Giuseppe
AU - Cecere, Fabiana
AU - Berardi, Rossana
AU - Pino, Maria Simona
AU - Martelli, Olga
AU - Gelibter, Alain
AU - Carta, Annamaria
AU - Vattemi, Emanuela
AU - Pagano, Maria
AU - Zullo, Alessandro
AU - Ferrari, Silvia
AU - Rossi, Antonio
AU - Novello, Silvia
PY - 2019/12/16
Y1 - 2019/12/16
N2 - Objectives: Molecular diagnostics and care of non-small cell lung cancer (NSCLC) are continuously evolving. Few data document the current strategies to manage advanced NSCLC patients beyond progression in clinical practice. Patients and methods: Be-TeaM is an Italian multi-center observational study conducted on consecutive EGFR-mutated stage IV NSCLC patients, progressed during/after a first-line EGFR-TKI. It consists of a retrospective phase, from first-line EGFR-TKI therapy start until study entry (i.e. beginning of the diagnostic process), and a prospective phase, until treatment choice or for 3 months if no therapy was prescribed. Primary objective was to describe the diagnostic and therapeutic approaches adopted after progression in a real-world setting. Results: Of 308 patients enrolled in 63 centers from July 2017 to June 2018, 289 were included in the analysis. In first line, 53.3 % received gefitinib, 32.5 % afatinib and 14.2 % erlotinib. The testing rate (i.e. rate of all patients undergone any biopsy -liquid and/or tissue- for the T790 M detection) was 90.7 %, with liquid biopsy being the most frequently executed. Of 262 biopsied patients, 64.5 % underwent only 1 liquid biopsy, 10.7 % only 1 tissue biopsy and 18.3 % >1 biopsy, both liquid and solid in 85.4 %. The T790M positivity rate was 45.3 %; of 166 patients undergone only a liquid biopsy and tested for the mutation, 39.8 % were T790M+ and 60.2 % T790M-/undetermined. By the observation end, 87.9 % patients had a post-progression treatment chosen, osimertinib being the most frequent among the T790M+. Conclusion: Be-TeaM provides the first snapshot of current practices for the management of NSCLC patients beyond progression in Italy; in clinical practice, assessing the T790M status is not always feasible.
AB - Objectives: Molecular diagnostics and care of non-small cell lung cancer (NSCLC) are continuously evolving. Few data document the current strategies to manage advanced NSCLC patients beyond progression in clinical practice. Patients and methods: Be-TeaM is an Italian multi-center observational study conducted on consecutive EGFR-mutated stage IV NSCLC patients, progressed during/after a first-line EGFR-TKI. It consists of a retrospective phase, from first-line EGFR-TKI therapy start until study entry (i.e. beginning of the diagnostic process), and a prospective phase, until treatment choice or for 3 months if no therapy was prescribed. Primary objective was to describe the diagnostic and therapeutic approaches adopted after progression in a real-world setting. Results: Of 308 patients enrolled in 63 centers from July 2017 to June 2018, 289 were included in the analysis. In first line, 53.3 % received gefitinib, 32.5 % afatinib and 14.2 % erlotinib. The testing rate (i.e. rate of all patients undergone any biopsy -liquid and/or tissue- for the T790 M detection) was 90.7 %, with liquid biopsy being the most frequently executed. Of 262 biopsied patients, 64.5 % underwent only 1 liquid biopsy, 10.7 % only 1 tissue biopsy and 18.3 % >1 biopsy, both liquid and solid in 85.4 %. The T790M positivity rate was 45.3 %; of 166 patients undergone only a liquid biopsy and tested for the mutation, 39.8 % were T790M+ and 60.2 % T790M-/undetermined. By the observation end, 87.9 % patients had a post-progression treatment chosen, osimertinib being the most frequent among the T790M+. Conclusion: Be-TeaM provides the first snapshot of current practices for the management of NSCLC patients beyond progression in Italy; in clinical practice, assessing the T790M status is not always feasible.
KW - Biopsy
KW - Clinical practice
KW - Italy
KW - Second-line treatment
KW - T790M
KW - Testing rate
UR - http://www.scopus.com/inward/record.url?scp=85076893081&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076893081&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2019.12.006
DO - 10.1016/j.lungcan.2019.12.006
M3 - Article
C2 - 31884129
AN - SCOPUS:85076893081
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
ER -